A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)

NCT06360354 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

350

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers

Interventions

DRUG: Anvumetostat
DRUG: Gemcitabine
DRUG: Nab-paclitaxel
DRUG: Modified FOLFIRINOX
DRUG: RMC-6236

Sponsor

Amgen